50377-49-6

Basic information

• Product Name: 4-chloro-6,7-dimethoxy-2-methylquinazoline
• Synonyms: 4-chloro-6,7-dimethoxy-2-methylquinazoline;2-Methyl-4-chloro-6,7-dimethoxyquinoline;4-Chloro-2-methyl-6,7-dimethoxyquinazoline
• CAS NO: 50377-49-6
• Molecular Formula: C₁₁H₁₁ClN₂O₂
• Molecular Weight: 238.673
• EINECS: 604-604-1
• Mol File: 50377-49-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 287℃
• Flash Point: 127℃
• Appearance: /
• Density: 1.281
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-chloro-6,7-dimethoxy-2-methylquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-6,7-dimethoxy-2-methylquinazoline(50377-49-6)
• EPA Substance Registry System: 4-chloro-6,7-dimethoxy-2-methylquinazoline(50377-49-6)

Safety Data

• Hazardous Substances Data: 50377-49-6(Hazardous Substances Data)

Usage

General Description

4-chloro-6,7-dimethoxy-2-methylquinazoline is a specific type of chemical compound that belongs to the class of organic compounds known as quinazolines, which are polycyclic aromatic compounds containing a quinazoline moiety, a structure made up of two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. The specific properties of 4-chloro-6,7-dimethoxy-2-methylquinazoline depend on its molecular structure which includes a chlorine atom, two methoxy groups and a methyl group attached to the quinazoline base. This chemical is not widely discussed in common literature and its uses are not explicitly listed, implying its use might be confined largely to scientific research and study. Both the exact physical properties (like color, odor, etc) and hazardous effects of this chemical aren't listed in general databases, thus handling and usage should be done with appropriate precaution, typically under the guidance of a chemistry professional.

InChI:InChI=1/C11H11ClN2O2/c1-6-13-8-5-10(16-3)9(15-2)4-7(8)11(12)14-6/h4-5H,1-3H3

Upstream product

• 35241-23-7 6,7-dimethoxy-2-methylquinazolin-4-ol 
• 63190-57-8 methyl 2-acetamido-4,5-diemthoxy benzoate 
• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 35241-23-7 6,7-dimethoxy-2-methylquinazoline-4(3H)-one 
• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 

Downstream Products

• 849218-01-5 6,7-dimethoxy-2-methyl-4-(4-nitro-phenoxy)-quinazoline 
• 849218-02-6 4-(6,7-dimethoxy-2-methyl-quinazolin-4-yloxy)-phenylamine 
• 849218-00-4 N-(4-fluorophenyl)-N'-(4-{[2-methyl-6,7-bis(methyloxy)quinazolin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide 

Relevant articles and documents

Design, synthesis and anticancer evaluation of structurally modified substituted aryl-quinazoline derivatives as anticancer agents

A new library of structurally modified aryl quinazoline-isoxazole (12a–j) derivatives have been designed, synthesized and characterized by 1HNMR, 13CNMR and mass spectral data. Further these compounds were evaluated for anticancer applications against four human cancer cell lines including PC3, DU-145 (prostate cancer), A549 (lung cancer) and MCF-7 (breast cancer) by utilizing the MTT assay. The results were compared with etoposide which was used as positive control. Most of the compounds showed good to moderate anticancer activities against the four cancer cell lines. Among them, compounds 12a, 12b, 12c, 12d and 12j exhibited more potent activities. Further, molecular docking studies were carried out for all synthesized compounds against the cancer targets Selective Human Androgen Receptor (PDB ID: 3V49) and Abl-Tyrosine kinase (PDB ID: 1IEP). All the docked ligands have exhibited good binding interactions with the targeted protein.

Fluorine-containing 6,7-dialkoxybiaryl-based inhibitors for phosphodiesterase 10 A: Synthesis and in vitro evaluation of inhibitory potency, selectivity, and metabolism

Based on the potent phosphodiesterase 10 A (PDE10A) inhibitor PQ-10, we synthesized 32 derivatives to determine relationships between their molecular structure and binding properties. Their roles as potential positron emission tomography (PET) ligands were evaluated, as well as their inhibitory potency toward PDE10A and other PDEs, and their metabolic stability was determined in vitro. According to our findings, halo-alkyl substituents at position 2 of the quinazoline moiety and/or halo-alkyloxy substituents at positions 6 or 7 affect not only the compounds′ affinity, but also their selectivity toward PDE10A. As a result of substituting the methoxy group for a monofluoroethoxy or difluoroethoxy group at position 6 of the quinazoline ring, the selectivity for PDE10A over PDE3A increased. The same result was obtained by 6,7-difluoride substitution on the quinoxaline moiety. Finally, fluorinated compounds (R)-7-(fluoromethoxy)-6-methoxy-4-(3-(quinoxaline-2-yloxy)pyrrolidine-1-yl) quinazoline (16 a), 19 a-d, (R)-tert-butyl-3-(6-fluoroquinoxalin-2-yloxy) pyrrolidine-1-carboxylate (29), and 35 (IC50 PDE10A 11-65 nM) showed the highest inhibitory potential. Further, fluoroethoxy substitution at position 7 of the quinazoline ring improved metabolic stability over that of the lead structure PQ-10. Fluor your health: Phosphodiesterase 10 A (PDE10A) has emerged as an attractive target for the development of 18F-labelled brain imaging agents for positron emission tomography. A series of fluorinated dialkoxybiaryl compounds were synthesized and evaluated as PDE10A inhibitors, assisted by QSAR docking studies. The 7-fluoromethoxy derivative appears to be a promising candidate for further development.

SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF

Selenophene compounds of formula (I) are described herein. In the compounds of Formula (I), ring A is a 6-membered aromatic fused ring, optionally containing one, two or three nitrogen atoms; a 5-membered heteroaromatic fused ring; or a mono- or bicyclic